Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment ... and regulate their blood sugar.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback